Quantitative analysis of tumor in bronchial biopsy specimens

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 448-452

  Coghlin, Caroline L ^a   Smith, Louise J ^a   Bakar, Salmah ^a   Stewart, Keith N ^a   Devereux, Graham S ^b   Nicolson, Marianne C ^c   Kerr, Keith M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Departments of Respiratory Medicine   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bronchial biopsy; Lung cancer; Molecular biology; Predictive markers; Quantitation

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHOSCOPY; BRONCHUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR BIOPSY; TUMOR VOLUME;

EID: 77951021505     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ca12c4     Document Type: Article

References (10)

1. Paez JG, Janne PA, Lee JC, et al. EGRF mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
3. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824. (Pubitemid 350002184)
4. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896. (Pubitemid 46849563)
5. Rosell R, Cuello M, Cecere F, et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol 2006;18:135-143. (Pubitemid 43740433)
6. Petty RD, Kerr KM, Murray GI, et al. The tumour transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small cell lung cancer. J Clin Oncol 2006;24:1729-1744.
7. Lim EH, Zhang S-L, Yu K, et al. An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximising the diagnostic procedure and the use of low volume lung biopsies. J Thorac Oncol 2007;2:387-396. (Pubitemid 47181692)
8. Tsao M-S. Should mutational analyses of tumour samples bypass histopathology? J Thorac Oncol 2007;2:375-376.
9. Sebo T, Bock B, Cheville J, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000;163:174-178.
10. Rubin M, Bassily N, Martin S, et al. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol 2000;24:183-189. (Pubitemid 30078706)